SCHEDULE: Ameriprise, Columbia Disclose 8.4% Stake in Pasithea

Ameriprise Financial and Columbia Management Investment Advisers have reported a combined beneficial ownership of 8.4% in Pasithea Therapeutics Corp. common stock.

Summary

• Ameriprise Financial, Inc. and its subsidiary, Columbia Management Investment Advisers, LLC, have filed a Schedule 13G.
• They collectively beneficially own 1,930,128 shares of Pasithea Therapeutics Corp. Common Stock.
• This represents 8.4% of the class of securities.
• The shares are held with shared voting power and shared dispositive power.
• The filing certifies that these securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as significant institutional ownership by reputable firms like Ameriprise and Columbia can lend credibility and stability to a company's shareholder base, though it provides no insight into operational performance.

Positives

• Significant institutional investment by Ameriprise Financial, Inc. and Columbia Management Investment Advisers, LLC, indicating a notable position in Pasithea Therapeutics Corp.
• The 8.4% stake suggests a substantial and passive interest from major financial institutions.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Schedule 13G filings are mandatory disclosures by institutional investors who acquire more than 5% of a company's voting stock, indicating significant passive investment interest rather than an intent to influence control. This filing highlights Ameriprise Financial's and Columbia Management's substantial position in Pasithea Therapeutics, a common occurrence for publicly traded companies attracting institutional capital.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be viewed positively, potentially signaling confidence in the company and improving liquidity.

Key Dates

Recommendation

While the filing indicates significant institutional interest from Ameriprise Financial and Columbia Management Investment Advisers, a Schedule 13G primarily reports passive ownership and does not provide sufficient operational or financial data to make a definitive 'buy' or 'sell' recommendation. The 8.4% stake is a notable position, suggesting institutional confidence, but further analysis of Pasithea Therapeutics' fundamentals and market conditions is required for a stronger investment stance. Therefore, a 'hold' recommendation is appropriate based solely on this ownership disclosure.

Keywords

Pasithea Therapeutics, Ameriprise Financial, Columbia Management, Schedule 13G, beneficial ownership, common stock, institutional investment, SEC filing